Oxyntomodulin, Mechanisms of Action in Relation to Appetite, Food Intake, Gastric Emptying and Energy Expenditure.

NCT ID: NCT01232244

Last Updated: 2013-12-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

15 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-10-31

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Tiny molecules (hormones) are released from the bowels and other organs to the bloodstream in response to meals in order to orchestrate the metabolism. Oxyntomodulin, GLP-1 and glucagon are all known to regulate parameters such as appetite, food intake and induce weight loss.

Therefore we want to investigate mechanistic relations between the three hormones.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Incretin Action Obesity

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Incretin hormones Glucagon Satiety Hunger Energy expenditure

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy young males

GLP-1 infusion

Intervention Type OTHER

1 pmol/kg/min

Glucagon infusion

Intervention Type OTHER

3ng/kg/min

Oxyntomodulin infusion

Intervention Type OTHER

3 pmol/kg/min

GLP-1 and glucagon infusion

Intervention Type OTHER

1 pmol/kg/min 3 ng/kg/min

Placebo

Intervention Type OTHER

NaCl 9 g/L infusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GLP-1 infusion

1 pmol/kg/min

Intervention Type OTHER

Glucagon infusion

3ng/kg/min

Intervention Type OTHER

Oxyntomodulin infusion

3 pmol/kg/min

Intervention Type OTHER

GLP-1 and glucagon infusion

1 pmol/kg/min 3 ng/kg/min

Intervention Type OTHER

Placebo

NaCl 9 g/L infusion

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Normal fasting plasma glucose
* Normal glucose tolerance
* Normal haemoglobin levels
* Informed content

Exclusion Criteria

* Diabetes
* Pre diabetes (impaired glucose tolerance or impaired fasting glucose)
* 1st degree relatives with diabetes
* Obesity (BMI \> 30)
* Inflammatory bowels disease
* Bowels surgery
* Nephropathy
* Liver disease
* Medication which cannot be on hold for 24h
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Gentofte, Copenhagen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jonatan I Bagger

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jonatan I Bagger, MD

Role: PRINCIPAL_INVESTIGATOR

Gentofte University Hospital, University of Copenhagen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gentofte University Hospital

Hellerup, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

References

Explore related publications, articles, or registry entries linked to this study.

Bagger JI, Holst JJ, Hartmann B, Andersen B, Knop FK, Vilsboll T. Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure. J Clin Endocrinol Metab. 2015 Dec;100(12):4541-52. doi: 10.1210/jc.2015-2335. Epub 2015 Oct 7.

Reference Type DERIVED
PMID: 26445112 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OXMDissek

Identifier Type: -

Identifier Source: org_study_id